Dust Mite Allergy News and Research

RSS

Researchers identify 'violent' physical processes which cause wheezing

A team of engineers has identified the 'violent' physical processes at work inside the lungs which cause wheezing, a condition which affects up to a quarter of the world's population.

24 Feb 2021

Bedroom air filters provide asthma relief for children

A new study by American and Chinese scientists, published in the journal JAMA Pediatrics, in April 2020, shows that a simple bedroom filter can help asthmatic children breathe better.

6 Apr 2020

Mite-proof covers may reduce severity of asthma exacerbations in allergic children

Bedcovers that form a barrier to house dust mites appear to reduce asthma flare-ups in children, according to new research published online, ahead of print in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

From The University of Manchester 10 Mar 2017

Study provides specific information about characteristics of dust mite allergens

Scientists from the National Institutes of Health have determined what differentiates dust mite allergens from the non-allergen proteins dust mites produce.

19 Oct 2016

Study finds age-dependent differences in expression of allergy to dust mites

In adults with a house dust mite allergy, a cascade of inflammatory signals on the surface of the airways leads to airway remodeling.

26 Aug 2016

Researchers one step closer to developing asthma vaccine

Researchers at VIB (a leading life sciences institute in Flanders, Belgium) and Ghent University have successfully established a causal relationship between exposure to so-called farm dust and protection against asthma and allergies.

4 Sep 2015

House dust mite allergy treatment: an interview with Steve Harris, CEO & Co-founder of Circassia

House dust mite allergy is a surprisingly prevalent problem. Something like 27% of the U.S. population and 20% of the European population are what’s called skin-prick test positive for house dust mites, which is a test for sensitivity to allergens to find out if a person is likely to get that allergy.

15 Oct 2013

Circassia: House dust mite allergy treatment meets primary endpoint in phase II clinical study

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced successful results from a phase II clinical study of its house dust mite allergy treatment (House Dust Mite-Synthetic Peptide Immuno-Regulatory Epitope [HDM-SPIRE] based on Circassia’s ToleroMune technology).

12 Sep 2013

AstraZeneca enters agreement with Pfizer for OTC NEXIUM

Pfizer Inc. today announced that it has entered into an agreement with AstraZeneca for the over-the-counter (OTC) rights for NEXIUM (esomeprazole magnesium), a leading prescription drug currently approved to treat the symptoms of gastroesophageal reflux disease (GERD).

14 Aug 2012

HAL Allergy initiates PURETHAL Mites PHASE II study

HAL Allergy B.V. today announced that it has included the first patient in its PHASE II dose range finding study.

31 Oct 2011

Researchers to develop house dust mite allergy vaccine that can cure asthma

Monash University researchers are working on a vaccine that could completely cure asthma brought on by house dust mite allergies.

22 Mar 2011

Circassia announces positive result from phase II T-cell vaccine study for house dust mite allergy

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced successful clinical results from a phase II study of its T-cell vaccine targeting house dust mite allergy.

18 Nov 2010

Circassia announces advancement in T-cell allergy vaccines development

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has further advanced the clinical development of three of its leading T-cell allergy vaccines.

30 Sep 2010

Ragweed allergy season more miserable for people with dog, cat or dust mite allergies

Ragweed allergy season can be even more miserable for those with dog, cat or dust mite allergies, according to new research. These year-round allergies appear to "pre-prime" the immune system so symptoms hit harder, according to a study recently published in the Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI).

19 Aug 2010

Encouraging results from Circassia's ToleroMune ragweed allergy T-cell vaccine phase II clinical trial

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that its ToleroMune(R) ragweed allergy T-cell vaccine achieved positive results in a recently completed phase II clinical trial. Ragweed allergy is particularly common in America, where it affects approximately 25% of the population. Circassia's latest clinical results follow two earlier successful phase II studies with the company's T-cell vaccine against cat allergy.

12 Feb 2010

Circassia commences Phase II trials of its T-cell vaccines against house dust mite and cat allergies

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has initiated phase II clinical trials of its T-cell vaccines targeting house dust mite and cat allergies. With the start of these studies, and the ongoing trial of Circassia's ragweed allergy (hay fever) T-cell vaccine, the company now has three clinical development programmes in phase II.

19 Jan 2010